Eikonoklastes Therapeutics Company
.jpg)
Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.
Total Funding:
$2 800 000
Headquarters:
Cincinnati, Ohio, United States
Funding Status:
Seed
Estimated Revenue:
$1M to $10M
Last Funding Type:
Seed
Last Funding Date:
2020-03-04
Founded Date:
2019-01-01
Industry:
Longevity